{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:38:45Z","timestamp":1793039925665,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T00:00:00Z","timestamp":1633564800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T00:00:00Z","timestamp":1633564800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Innovation Group Project of Shanghai Municipal Health Commission","award":["2019CXJQ03"],"award-info":[{"award-number":["2019CXJQ03"]}]},{"DOI":"10.13039\/501100012247","name":"Program of Shanghai Academic\/ Technology Research Leader","doi-asserted-by":"crossref","award":["18XD1400900"],"award-info":[{"award-number":["18XD1400900"]}],"id":[{"id":"10.13039\/501100012247","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Shanghai Municipal Key Clinical Specialty","award":["Laboratory Medicine, No.shslczdzk03303"],"award-info":[{"award-number":["Laboratory Medicine, No.shslczdzk03303"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Macroprolactin is responsible for pseudohyperprolactinemia and is a common pitfall of the prolactin immunoassay. We aimed to determine the frequency of macroprolactinemia in Chinese hyperprolactinemic patients using monomeric prolactin discriminated by precipitation with polyethylene glycol (PEG).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Post-PEG monomeric prolactin gender-specific reference intervals were established for the Elecsys immunoassay method (Roche Diagnostics) using sera from healthy female (<jats:italic>n<\/jats:italic>\u2009=\u2009120) and male (<jats:italic>n<\/jats:italic>\u2009=\u2009120) donors. The reference intervals were validated using 20 macroprolactinemic (as assessed by gel filtration chromatography (GFC)) sera samples, and presence of monomeric prolactin was discriminated by GFC. Patients with high total prolactin were then screened by PEG precipitation to analyze macroprolactin. The demographic and biochemical details of patients with true hyperprolactinemia and macroprolactinemia were compared.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Reference intervals for monomeric prolactin in females and males were 3.4\u201318.5 and 2.7\u201313.1 ng\/mL, respectively. Among 1140 hyperprolactinemic patients, macroprolactinemia was identified in 261 (22.9\u2009%) patients while the other 879 (77.1\u2009%) patients were diagnosed with true hyperprolactinemia. Menstrual disturbances were the most common clinical feature in both groups. Galactorrhea, amenorrhea, and visual disturbances occurred more frequently in true hyperprolactinemic patients (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The prevalence of macroprolactin in Chinese patients with hyperprolactinemia was described for the first time. Monomeric prolactin concentration, along with a reference interval screening with PEG precipitation, provides a diagnostic approach for hyperprolactinemia with improved accuracy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12902-021-00861-z","type":"journal-article","created":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T10:23:19Z","timestamp":1633602199000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Establishment of reference intervals of monomeric prolactin to identify macroprolactinemia in Chinese patients with increased total prolactin"],"prefix":"10.1186","volume":"21","author":[{"given":"Yao","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajin","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Buyue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huating","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongying","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijin","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,7]]},"reference":[{"key":"861_CR1","doi-asserted-by":"crossref","unstructured":"Kavanagh, L; McKenna, TJ; Fahie-Wilson, MN; et al. Specificity and clinical utility of methods for the detection of macroprolactin. [J]. Clin Chem.2006,52(7):1366\u201372","DOI":"10.1373\/clinchem.2005.065854"},{"issue":"3\u20134","key":"861_CR2","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.cca.2009.10.020","volume":"411","author":"CR McCudden","year":"2010","unstructured":"McCudden, CR; Sharpless, JL; Grenache, DG; Comparison of multiple methods for identification of hyperprolactinemia in the presence of macroprolactin. [J]. Clin Chim Acta.2010,411(3\u20134):155\u201360","journal-title":"Clin Chim Acta"},{"key":"861_CR3","unstructured":"Chen, YJ; Song, GZ; Wang, ZN; A new criteria for screening macroprolactinemia using polyethylene glycol treatment combined with different assays for prolactin. [J]. Eur Rev Med Pharmacol Sci.2016,20(9):1788\u201394"},{"issue":"2","key":"861_CR4","doi-asserted-by":"publisher","first-page":"93","DOI":"10.29271\/jcpsp.2018.02.93","volume":"28","author":"NA Sherazi","year":"2018","unstructured":"Sherazi, NA; Baig, MZ; Khan, AH; Frequency of Macroprolactin in Hyperprolactinemia. [J]. J Coll Physicians Surg Pak.2018,28(2):93\u201397","journal-title":"J Coll Physicians Surg Pak"},{"issue":"6","key":"861_CR5","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.tjog.2017.10.002","volume":"56","author":"M Kasum","year":"2017","unstructured":"Kasum, M; Oreskovic, S; Cehic, E; et al. Laboratory and clinical significance of macroprolactinemia in women with hyperprolactinemia. [J]. Taiwan J Obstet Gynecol.2017,56(6):719\u2013724","journal-title":"Taiwan J Obstet Gynecol"},{"key":"861_CR6","doi-asserted-by":"crossref","unstructured":"Beshyah, SA; Sherif, IH; Chentli, F; et al. Management of prolactinomas: a survey of physicians from the Middle East and North Africa. [J]. Pituitary.2017,20(2):231\u2013240","DOI":"10.1007\/s11102-016-0767-5"},{"issue":"8","key":"861_CR7","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1515\/cclm-2018-0074","volume":"56","author":"JH Barth","year":"2018","unstructured":"Barth, JH; Lippiatt, CM; Gibbons, SG; et al. Observational studies on macroprolactin in a routine clinical laboratory. [J]. Clin Chem Lab Med.2018,56(8):1259\u20131262","journal-title":"Clin Chem Lab Med"},{"issue":"2","key":"861_CR8","doi-asserted-by":"publisher","first-page":"020706","DOI":"10.11613\/BM.2019.020706","volume":"29","author":"M Sostaric","year":"2019","unstructured":"Sostaric, M; Bokulic, A; Marijancevic, D; et al. Optimizing laboratory defined macroprolactin algorithm. [J]. Biochem Med (Zagreb).2019,29(2):020706","journal-title":"Biochem Med (Zagreb)"},{"key":"861_CR9","doi-asserted-by":"crossref","unstructured":"Vilar, L; Vilar, CF; Lyra, R; et al. Pitfalls in the Diagnostic Evaluation of Hyperprolactinemia. [J]. Neuroendocrinology.2019,109(1):7\u201319","DOI":"10.1159\/000499694"},{"issue":"1","key":"861_CR10","first-page":"3","volume":"39","author":"M Saleem","year":"2018","unstructured":"Saleem, M; Martin, H; Coates, P; Prolactin Biology and Laboratory Measurement: An Update on Physiology and Current Analytical Issues. [J]. Clin Biochem Rev.2018,39(1):3\u201316","journal-title":"Clin Biochem Rev"},{"issue":"11","key":"861_CR11","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1515\/cclm-2016-0902","volume":"55","author":"M Overgaard","year":"2017","unstructured":"Overgaard, M; Pedersen, SM; Serum prolactin revisited: parametric reference intervals and cross platform evaluation of polyethylene glycol precipitation-based methods for discrimination between hyperprolactinemia and macroprolactinemia. [J]. Clin Chem Lab Med.2017,55(11):1744\u20131753","journal-title":"Clin Chem Lab Med"},{"key":"861_CR12","doi-asserted-by":"crossref","unstructured":"Beltran, L; Fahie-Wilson, MN; McKenna, TJ; et al. Serum total prolactin and monomeric prolactin reference intervals determined by precipitation with polyethylene glycol: evaluation and validation on common immunoassay platforms. [J]. Clin Chem.2008,54(10):1673\u201381","DOI":"10.1373\/clinchem.2008.105312"},{"key":"861_CR13","doi-asserted-by":"crossref","unstructured":"Chanson, P; Maiter, D; The epidemiology, diagnosis and treatment of Prolactinomas: The old and the new. [J]. Best Pract Res Clin Endocrinol Metab.2019,33(2):101290","DOI":"10.1016\/j.beem.2019.101290"},{"key":"861_CR14","doi-asserted-by":"crossref","unstructured":"Fahie-Wilson, M; In hyperprolactinemia, testing for macroprolactin is essential. [J]. Clin Chem.2003,49(9):1434\u20136","DOI":"10.1373\/49.9.1434"},{"key":"861_CR15","doi-asserted-by":"crossref","unstructured":"Che Soh, NAA; Yaacob, NM; Omar, J; et al.Global Prevalence of Macroprolactinemia among Patients with Hyperprolactinemia: A Systematic Review and Meta-Analysis.[J].Int J Environ Res Public Health.2020,17(21)","DOI":"10.3390\/ijerph17218199"},{"issue":"7","key":"861_CR16","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1210\/jc.2010-0114","volume":"95","author":"IR Wallace","year":"2010","unstructured":"Wallace, IR; Satti, N; Courtney, CH; et al. Ten-year clinical follow-up of a cohort of 51 patients with macroprolactinemia establishes it as a benign variant. [J]. J Clin Endocrinol Metab.2010,95(7):3268\u201371","journal-title":"J Clin Endocrinol Metab."},{"issue":"7","key":"861_CR17","doi-asserted-by":"publisher","first-page":"3927","DOI":"10.1210\/jc.2004-2234","volume":"90","author":"J Gibney","year":"2005","unstructured":"Gibney, J; Smith, TP; McKenna, TJ; The impact on clinical practice of routine screening for macroprolactin. [J]. J Clin Endocrinol Metab.2005,90(7):3927\u201332","journal-title":"J Clin Endocrinol Metab."},{"key":"861_CR18","doi-asserted-by":"crossref","unstructured":"Suliman, AM; Smith, TP; Gibney, J; et al. Frequent misdiagnosis and mismanagement of hyperprolactinemic patients before the introduction of macroprolactin screening: application of a new strict laboratory definition of macroprolactinemia. [J]. Clin Chem.2003,49(9):1504\u20139","DOI":"10.1373\/49.9.1504"},{"key":"861_CR19","doi-asserted-by":"crossref","unstructured":"Hauache, OM; Rocha, AJ; Maia, AC; et al. Screening for macroprolactinaemia and pituitary imaging studies. [J]. Clin Endocrinol (Oxf).2002,57(3):327\u201331","DOI":"10.1046\/j.1365-2265.2002.01586.x"},{"key":"861_CR20","doi-asserted-by":"crossref","unstructured":"Veljkovic, K; Servedio, D; Don-Wauchope, AC; Reporting of post-polyethylene glycol prolactin: precipitation by polyethylene glycol 6000 or polyethylene glycol 8000 will change reference intervals for monomeric prolactin.[J].Ann Clin Biochem.2012,49(Pt 4):402\u20134","DOI":"10.1258\/acb.2011.011238"},{"key":"861_CR21","doi-asserted-by":"crossref","unstructured":"Yang, W; Guo, Z; Zhou, Y; et al.Optimization of a Screening Method for Macroprolactinemia.[J].J Chromatogr B Analyt Technol Biomed Life Sci.2021,1175():122723","DOI":"10.1016\/j.jchromb.2021.122723"},{"issue":"5","key":"861_CR22","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.beem.2013.07.002","volume":"27","author":"M Fahie-Wilson","year":"2013","unstructured":"Fahie-Wilson, M; Smith, TP; Determination of prolactin: the macroprolactin problem. [J]. Best Pract Res Clin Endocrinol Metab.2013,27(5):725\u201342","journal-title":"Best Pract Res Clin Endocrinol Metab."},{"issue":"7","key":"861_CR23","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1111\/j.1365-2362.2007.01823.x","volume":"37","author":"F Donadio","year":"2007","unstructured":"Donadio, F; Barbieri, A; Angioni, R; et al.Patients with macroprolactinaemia: clinical and radiological features.[J].Eur J Clin Invest.2007,37(7):552\u20137","journal-title":"J].Eur J Clin Invest"},{"key":"861_CR24","doi-asserted-by":"crossref","unstructured":"Aisaka, K; Tsuchiya, F; Sueta, M; et al.Impact of macroprolactin on galactorrhea and the rate of patients possibly affected by macroprolactin.[J].Endocr J.2018,65(2):203\u2013211","DOI":"10.1507\/endocrj.EJ17-0358"},{"issue":"2","key":"861_CR25","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1210\/jc.2010-1692","volume":"96","author":"S Melmed","year":"2011","unstructured":"Melmed, S; Casanueva, FF; Hoffman, AR; et al.Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline.[J].J Clin Endocrinol Metab.2011,96(2):273\u201388","journal-title":"J Clin Endocrinol Metab"},{"key":"861_CR26","doi-asserted-by":"crossref","unstructured":"Halperin Rabinovich, I; C\u00e1mara G\u00f3mez, R; Garc\u00eda Mouriz, M; et al.[Clinical guidelines for diagnosis and treatment of prolactinoma and hyperprolactinemia].[J].Endocrinol Nutr.2013,60(6):308\u201319","DOI":"10.1016\/j.endoen.2012.11.009"},{"key":"861_CR27","doi-asserted-by":"crossref","unstructured":"Vilar, L; Abucham, J; Albuquerque, JL; et al.Controversial issues in the management of hyperprolactinemia and prolactinomas - An overview by the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism.[J].Arch Endocrinol Metab.2018,62(2):236\u2013263","DOI":"10.20945\/2359-3997000000032"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-021-00861-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-021-00861-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-021-00861-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T22:37:13Z","timestamp":1634596633000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-021-00861-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,7]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["861"],"URL":"https:\/\/doi.org\/10.1186\/s12902-021-00861-z","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,7]]},"assertion":[{"value":"4 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The equal contribution information of the authors was missed in the original paper. The article has been updated to rectify the errors.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Our study was approved by the Huashan Hospital Foundation Ethical Committee (reference number KY2019-395). Written informed consent was obtained from all participants. All clinical investigations were conducted according to the principles expressed in the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Patient consent for research use of data was obtained for each case presented.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"197"}}